FDA
-
-
-
-
-
-
-
Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features
-
-
-
-
-
-
-
Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations at the American College of Neuropsychopharmacology 61st Annual Meeting
-
-
-
-
-
-
-
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Needham & Company Previews Intra-Cellular Therapies (ITCI) Dec. 17th PDUFA for Caplyta
-
-
-
-
-
-
-
Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Intra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual Meeting
-
-
-
-
-
-
-
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
-
251,395 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All